| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Resynchronization Therapy | 44 | 2025 | 89 | 12.450 |
Why?
|
| Bundle of His | 26 | 2025 | 57 | 7.870 |
Why?
|
| Bundle-Branch Block | 28 | 2025 | 66 | 7.780 |
Why?
|
| Electrocardiography | 36 | 2025 | 559 | 5.390 |
Why?
|
| Defibrillators, Implantable | 22 | 2024 | 190 | 5.070 |
Why?
|
| Heart Failure | 32 | 2025 | 1438 | 4.730 |
Why?
|
| Atrial Fibrillation | 19 | 2024 | 444 | 4.220 |
Why?
|
| Tachycardia, Ventricular | 19 | 2025 | 180 | 3.270 |
Why?
|
| Cardiac Pacing, Artificial | 18 | 2025 | 119 | 3.150 |
Why?
|
| Catheter Ablation | 25 | 2025 | 365 | 3.060 |
Why?
|
| Heart Conduction System | 17 | 2024 | 140 | 2.810 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 12 | 2024 | 82 | 1.990 |
Why?
|
| Arrhythmias, Cardiac | 14 | 2024 | 233 | 1.630 |
Why?
|
| Heart Ventricles | 15 | 2025 | 826 | 1.530 |
Why?
|
| Heart Rate | 11 | 2024 | 533 | 1.520 |
Why?
|
| Treatment Outcome | 53 | 2025 | 9230 | 1.440 |
Why?
|
| Pacemaker, Artificial | 8 | 2025 | 116 | 1.270 |
Why?
|
| Stroke Volume | 7 | 2025 | 550 | 1.260 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 7 | 2019 | 20 | 1.140 |
Why?
|
| Ventricular Function, Left | 11 | 2025 | 677 | 1.120 |
Why?
|
| Humans | 117 | 2025 | 95983 | 1.090 |
Why?
|
| Aged | 62 | 2025 | 20922 | 1.020 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 4 | 2024 | 29 | 1.000 |
Why?
|
| Electric Countershock | 4 | 2024 | 77 | 0.990 |
Why?
|
| Echocardiography | 10 | 2025 | 1010 | 0.900 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2019 | 81 | 0.860 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2024 | 67 | 0.860 |
Why?
|
| Middle Aged | 50 | 2025 | 28296 | 0.820 |
Why?
|
| Heart Septum | 3 | 2024 | 51 | 0.810 |
Why?
|
| Male | 69 | 2025 | 45784 | 0.800 |
Why?
|
| Female | 70 | 2025 | 49971 | 0.800 |
Why?
|
| Bradycardia | 4 | 2025 | 47 | 0.770 |
Why?
|
| Body Surface Potential Mapping | 5 | 2021 | 32 | 0.760 |
Why?
|
| Cardiomyopathies | 7 | 2020 | 318 | 0.750 |
Why?
|
| Mitral Valve Insufficiency | 4 | 2019 | 210 | 0.730 |
Why?
|
| Prospective Studies | 23 | 2024 | 4691 | 0.720 |
Why?
|
| Atrioventricular Block | 4 | 2024 | 32 | 0.690 |
Why?
|
| Heart Atria | 4 | 2024 | 297 | 0.690 |
Why?
|
| Registries | 6 | 2025 | 998 | 0.660 |
Why?
|
| Anticoagulants | 2 | 2023 | 465 | 0.620 |
Why?
|
| Purkinje Fibers | 1 | 2019 | 27 | 0.590 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 26 | 0.590 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 77 | 0.570 |
Why?
|
| Retrospective Studies | 29 | 2025 | 10309 | 0.570 |
Why?
|
| Action Potentials | 3 | 2024 | 629 | 0.520 |
Why?
|
| Atrioventricular Node | 5 | 2024 | 39 | 0.520 |
Why?
|
| Cicatrix | 4 | 2024 | 77 | 0.510 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 162 | 0.490 |
Why?
|
| Atrial Flutter | 4 | 2020 | 42 | 0.480 |
Why?
|
| Follow-Up Studies | 18 | 2025 | 3922 | 0.470 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 20 | 0.460 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 219 | 0.450 |
Why?
|
| Syncope, Vasovagal | 2 | 2025 | 8 | 0.440 |
Why?
|
| Hospitalization | 4 | 2018 | 946 | 0.430 |
Why?
|
| Cause of Death | 1 | 2015 | 278 | 0.420 |
Why?
|
| Ventricular Fibrillation | 4 | 2024 | 78 | 0.390 |
Why?
|
| Incidence | 7 | 2024 | 1722 | 0.370 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 57 | 0.370 |
Why?
|
| Equipment Failure | 1 | 2012 | 133 | 0.360 |
Why?
|
| Myocarditis | 1 | 2012 | 62 | 0.360 |
Why?
|
| Growth Differentiation Factor 10 | 1 | 2011 | 1 | 0.350 |
Why?
|
| Risk Factors | 14 | 2024 | 5984 | 0.350 |
Why?
|
| Antigens, Ly | 1 | 2011 | 37 | 0.340 |
Why?
|
| Postoperative Complications | 3 | 2021 | 2603 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2014 | 346 | 0.330 |
Why?
|
| Epicardial Mapping | 2 | 2021 | 12 | 0.330 |
Why?
|
| Sick Sinus Syndrome | 2 | 2021 | 9 | 0.320 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 133 | 0.320 |
Why?
|
| Ventricular Remodeling | 7 | 2020 | 114 | 0.320 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 273 | 0.310 |
Why?
|
| Device Removal | 2 | 2021 | 169 | 0.300 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 349 | 0.290 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 7220 | 0.280 |
Why?
|
| Mitral Valve | 3 | 2020 | 280 | 0.280 |
Why?
|
| GTPase-Activating Proteins | 1 | 2008 | 68 | 0.270 |
Why?
|
| Wnt Proteins | 1 | 2008 | 131 | 0.270 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 135 | 0.270 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 1817 | 0.270 |
Why?
|
| Time Factors | 8 | 2024 | 5592 | 0.260 |
Why?
|
| Recurrence | 8 | 2024 | 1232 | 0.260 |
Why?
|
| beta Catenin | 1 | 2008 | 266 | 0.250 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2007 | 134 | 0.240 |
Why?
|
| Myocardial Ischemia | 4 | 2019 | 167 | 0.240 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 173 | 0.240 |
Why?
|
| Ventricular Septum | 2 | 2024 | 16 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2019 | 3114 | 0.230 |
Why?
|
| United States | 10 | 2025 | 7777 | 0.220 |
Why?
|
| Risk Assessment | 7 | 2024 | 2493 | 0.220 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1275 | 0.210 |
Why?
|
| Myocardium | 2 | 2020 | 606 | 0.210 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2004 | 9 | 0.210 |
Why?
|
| Patient Selection | 2 | 2022 | 708 | 0.210 |
Why?
|
| Hemodynamics | 2 | 2024 | 776 | 0.200 |
Why?
|
| Particulate Matter | 1 | 2025 | 124 | 0.200 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 12 | 0.200 |
Why?
|
| Air Pollution | 1 | 2025 | 107 | 0.200 |
Why?
|
| Electrodes, Implanted | 3 | 2012 | 222 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 202 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 173 | 0.190 |
Why?
|
| Medicare | 3 | 2024 | 458 | 0.190 |
Why?
|
| Vaccination | 1 | 2024 | 310 | 0.180 |
Why?
|
| Feasibility Studies | 6 | 2021 | 819 | 0.180 |
Why?
|
| Microfluidics | 1 | 2022 | 57 | 0.180 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 458 | 0.180 |
Why?
|
| Heart-Assist Devices | 4 | 2018 | 903 | 0.180 |
Why?
|
| Ventricular Premature Complexes | 1 | 2021 | 14 | 0.180 |
Why?
|
| Exercise | 1 | 2025 | 356 | 0.180 |
Why?
|
| Prognosis | 5 | 2023 | 3994 | 0.170 |
Why?
|
| Treatment Failure | 3 | 2017 | 297 | 0.170 |
Why?
|
| Crohn Disease | 2 | 2007 | 809 | 0.170 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2021 | 12 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 62 | 0.170 |
Why?
|
| Electrophysiology | 1 | 2021 | 408 | 0.160 |
Why?
|
| Machine Learning | 1 | 2024 | 349 | 0.160 |
Why?
|
| Gadolinium | 1 | 2020 | 106 | 0.160 |
Why?
|
| Pulmonary Veins | 2 | 2012 | 111 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1982 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 132 | 0.160 |
Why?
|
| Global Health | 2 | 2021 | 214 | 0.160 |
Why?
|
| Vena Cava, Superior | 1 | 2020 | 58 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 126 | 0.150 |
Why?
|
| Cardiac Catheters | 1 | 2019 | 20 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 162 | 0.150 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 334 | 0.140 |
Why?
|
| Tachycardia | 1 | 2018 | 40 | 0.140 |
Why?
|
| Computer Security | 1 | 2018 | 17 | 0.140 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2018 | 2 | 0.140 |
Why?
|
| Equipment Design | 2 | 2025 | 435 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2022 | 1158 | 0.140 |
Why?
|
| Myocardial Contraction | 1 | 2019 | 253 | 0.140 |
Why?
|
| Quality of Life | 2 | 2024 | 1816 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2021 | 460 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 401 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2018 | 128 | 0.130 |
Why?
|
| Forecasting | 2 | 2015 | 317 | 0.130 |
Why?
|
| Cardiology | 1 | 2017 | 134 | 0.120 |
Why?
|
| Glomerular Filtration Barrier | 1 | 2015 | 1 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 848 | 0.120 |
Why?
|
| Coronary Angiography | 2 | 2014 | 261 | 0.110 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1195 | 0.110 |
Why?
|
| Adult | 9 | 2025 | 28630 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 33 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 645 | 0.100 |
Why?
|
| Cardiac Conduction System Disease | 2 | 2023 | 8 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 502 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 121 | 0.100 |
Why?
|
| Walking | 1 | 2014 | 106 | 0.100 |
Why?
|
| Pharyngitis | 1 | 2012 | 15 | 0.090 |
Why?
|
| Streptococcus pyogenes | 1 | 2012 | 35 | 0.090 |
Why?
|
| Animals | 4 | 2022 | 28905 | 0.090 |
Why?
|
| Creatine Kinase | 1 | 2012 | 53 | 0.090 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 6 | 0.090 |
Why?
|
| Troponin T | 1 | 2012 | 44 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 49 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 199 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 193 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 258 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 332 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2024 | 311 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1962 | 0.090 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 3 | 0.090 |
Why?
|
| Smad3 Protein | 1 | 2011 | 25 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 1320 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 89 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 52 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 314 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2013 | 364 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 383 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 2859 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 119 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2012 | 308 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 432 | 0.070 |
Why?
|
| Biomarkers | 2 | 2012 | 1932 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2011 | 3585 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 436 | 0.070 |
Why?
|
| Axin Protein | 1 | 2008 | 4 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 45 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 7025 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2008 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1618 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cytosol | 1 | 2008 | 197 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1958 | 0.070 |
Why?
|
| Contrast Media | 2 | 2024 | 1097 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 2342 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1642 | 0.060 |
Why?
|
| Behavior | 1 | 2007 | 87 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2887 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 128 | 0.060 |
Why?
|
| Perception | 1 | 2007 | 185 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 890 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2162 | 0.060 |
Why?
|
| Clinical Clerkship | 1 | 2007 | 125 | 0.060 |
Why?
|
| Zebrafish | 1 | 2008 | 342 | 0.060 |
Why?
|
| Mice | 2 | 2011 | 12528 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1347 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 1017 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2088 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 447 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2007 | 312 | 0.060 |
Why?
|
| Ventricular Pressure | 1 | 2024 | 48 | 0.050 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2024 | 12 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 1350 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2044 | 0.050 |
Why?
|
| Heart Injuries | 1 | 2024 | 24 | 0.050 |
Why?
|
| Syncope | 1 | 2024 | 37 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1810 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2024 | 140 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 2537 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1230 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3485 | 0.050 |
Why?
|
| Atropine | 1 | 2023 | 61 | 0.050 |
Why?
|
| Heart Block | 1 | 2023 | 37 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2024 | 180 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 219 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 398 | 0.050 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2022 | 8 | 0.050 |
Why?
|
| Viscosity | 1 | 2022 | 51 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 386 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 184 | 0.050 |
Why?
|
| Students, Medical | 1 | 2007 | 455 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 221 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 156 | 0.040 |
Why?
|
| Survival Rate | 2 | 2015 | 1978 | 0.040 |
Why?
|
| Endocardium | 1 | 2020 | 103 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 365 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1014 | 0.040 |
Why?
|
| Vascular System Injuries | 1 | 2020 | 37 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2012 | 1540 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 1562 | 0.040 |
Why?
|
| Pericardium | 1 | 2019 | 84 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1741 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 125 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 62 | 0.030 |
Why?
|
| Heart | 1 | 2020 | 596 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 206 | 0.030 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2015 | 6 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 633 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 38 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 59 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Capillaries | 1 | 2014 | 85 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 48 | 0.030 |
Why?
|
| Massachusetts | 1 | 2013 | 35 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 99 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2012 | 159 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 311 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1176 | 0.020 |
Why?
|
| Child | 1 | 2023 | 7626 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 904 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 22 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 193 | 0.020 |
Why?
|
| Adolescent | 1 | 2004 | 9872 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 666 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 936 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 984 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1018 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 935 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2014 | 816 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 38 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 113 | 0.020 |
Why?
|
| Japan | 1 | 2007 | 313 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1166 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 909 | 0.010 |
Why?
|
| Reoperation | 1 | 2007 | 712 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 683 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 636 | 0.010 |
Why?
|